Three engines of a pharma group
For Hikma Pharmaceuticals (LSE:HIK), Demand across its injectable, branded and generic medicines is what drives the FTSE 100 company. Hikma is a pharmaceutical group operating through three segments: Injectables, which supplies hospital injectable medicines mainly in developed markets; Branded, which sells medicines across the Middle East and North Africa; and Generics, its United States generic-drugs business, Hikma Rx. This Diversification across product types and geographies gives the group multiple demand drivers and some resilience, since strength in one area can offset weakness in another. How these markets evolve therefore shapes Hikma's performance.
A solid first half
The half-year 2026 results, for the six months ended 30 June 2026, showed steady progress. Core Revenue rose 4% to $1,728m, core operating profit rose 9% to $405m at a Margin of 23.4%, up 90 basis points, and core Basic Earnings Per Share rose 5% to 128 cents, according to the company's reporting. The Interim Dividend rose 6% to 38 cents, and Operating Cash Flow rose 33% to $214m. By segment, Branded revenue rose 15% to $502m, Hikma Rx was flat at $520m, and Injectables was flat at $685m with core operating profit down 8%. These are reported figures in US dollars, while the shares trade in sterling. Hikma reiterated full-year guidance for revenue growth of 2% to 4% and core operating profit of $720m to $770m.
Diversification in action
The half illustrates the value of Hikma's diversified model: strong 15% growth in the Branded Middle East and North Africa Business offset flat performance in the United States generics and injectables segments. Injectables, a historically high-margin area, saw profit dip, while Branded provided the growth. Rising margins and strong cash flow point to good operational management. The reiterated guidance suggests confidence in the full-year outlook. The main questions are whether the injectables and generics businesses can return to growth, and whether the Branded momentum continues, since the balance across the three segments determines the group's overall trajectory. Operating cash flow rising 33% to $214m is a particularly encouraging signal, since strong cash generation supports both the dividend, up 6% to 38 cents, and continued Investment in the pipeline and manufacturing. The 8% dip in injectables core operating profit is the main soft spot, reflecting competition and pricing in a reliable earner, so its recovery matters overall.
Opportunities and risks
The opportunity is durable demand for essential medicines across Hikma's three segments, with diversification providing resilience and the Branded business offering growth, supported by improving margins and strong cash generation. The risks are those of the pharmaceutical sector: pricing pressure in United States generics, competition, and regulatory and Manufacturing requirements that can affect specific products, as the injectables profit dip showed. Exposure to the Middle East and North Africa brings regional and currency risks, and the dollar reporting adds a translation layer for sterling holders. Drug pricing policy in the United States is a continuing consideration for any generics-exposed company.
The bottom line
Injectable and generic drug demand shapes Hikma across its three segments, and the first half of 2026 showed the diversified model working, with strong Branded growth offsetting flat generics and injectables and lifting overall profit and margins. Core operating profit rose 9%, cash flow was strong, and full-year guidance was reiterated. For readers, the questions are whether injectables and United States generics return to growth, whether Branded momentum persists, and how drug pricing and regulation evolve. The breadth of Hikma's portfolio provides resilience and steady cash generation, but the balance across its segments and United States pricing pressures are the key factors for shareholders over time.






Please wait processing your request...